Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.